glp 1 or tirzepatide GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Tirzepatide vs Semaglutide | Understanding
Description
Dry eye in diabetic patients
What is particularly challenging (and well-known to those aware of the pharmaceutical industrys history) is how the label safe and effective can sometimes conceal rare but devastating side effects
Some healthcare specialists say that an injection enabling people to eat dramatically fewer calories in a day resembles nothing less than a drug-induced or at least, a drug-encouraged eating disorder
They demonstrate a favorable safety profile, allowing for co-administration with most other glucose-lowering medications, except vildagliptin
The FDA-approved labeling for semaglutide and tirzepatide includes a boxed warning regarding thyroid C-cell tumors observed in rodent studies
doi: 10.1016/S0140-6736(18)32260-8 [DOI] [PubMed] [Google Scholar] 112
